Lilly underlines what's at stake in Brexit talks

2 March 2018

Plenty of senior industry figures and major companies have tried to explain the risks posed to parts of pharma’s value chain by Brexit since the UK public voted to leave the European Union (EU) in June 2016.

So far the warnings issued in the media and lobbying to government have not yet given the industry the firm guarantees they are seeking, so companies remain in the dark about what the UK’s exit deal with the EU might look like as the two sides start discussing the future relationship and transition deal.

"Our UK presence has now become Lilly’s biggest research operation outside of the USA"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK